News coverage about AzurRx BioPharma (NASDAQ:AZRX) has been trending somewhat positive recently, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AzurRx BioPharma earned a news impact score of 0.08 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.6094756646434 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

AzurRx BioPharma (AZRX) traded down $0.09 during midday trading on Thursday, reaching $3.11. The company had a trading volume of 24,200 shares, compared to its average volume of 32,817. AzurRx BioPharma has a one year low of $2.40 and a one year high of $5.25.

Separately, HC Wainwright set a $8.00 price target on AzurRx BioPharma and gave the stock a “buy” rating in a report on Friday, November 17th.

ILLEGAL ACTIVITY NOTICE: This article was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at

AzurRx BioPharma Company Profile

AzurRx BioPharma, Inc is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101.

Insider Buying and Selling by Quarter for AzurRx BioPharma (NASDAQ:AZRX)

Receive News & Ratings for AzurRx BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma Inc and related companies with's FREE daily email newsletter.